SSRIs in pregnancy do not affect infant growth
Selective serotonin reuptake inhibitors (SSRIs) taken by a woman during pregnancy do not impact her infant's growth during the first year of life, reports a new small study.
Selective serotonin reuptake inhibitors (SSRIs) taken by a woman during pregnancy do not impact her infant's growth during the first year of life, reports a new small study.
The study, published March 20, 2013, on the website of The American Journal of Psychiatry, shows that infants born to mothers who took SSRIs had similar weights, lengths, and head circumferences over the course of their first year as infants born to women who did not take SSRIs.
For the study, pregnant women were evaluated at weeks 20, 30, and 36 of gestation, and mother-and-infant pairs were assessed at 2, 12, 26, and 52 weeks postpartum. Three nonoverlapping groups of women were defined according to their pregnancy exposures: 1) no SSRI and no depression (N=97), 2) SSRI (N=46), and 3) major depression without SSRI (N=31). Maternal demographic and clinical characteristics and newborn outcomes were compared among exposure groups. Infant weight, length, and head circumference were measured by a physician or physician assistant who was blind to depression and SSRI exposure status at each postpartum time point.
The researchers found that neither antenatal major depression nor SSRI exposure was significantly associated with infant weight, length, or head circumference. In addition, the researchers noted, the interaction of group and prepregnancy body mass index was evaluated, and no significant synergistic effect was identified.
How plasma biomarkers illuminate brain health in women with HIV
December 4th 2023Discoveries from a comprehensive study reveal specific plasma biomarkers that may serve as indicators of neurological well-being in individuals living with HIV, shedding light on potential links to Alzheimer's disease and emphasizing the importance of early detection for improved outcomes.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Link between reproductive life span and postmenopausal muscle mass
November 30th 2023A recent study in Menopause, the journal of The Menopause Society, suggests that a longer reproductive life span and later age at menopause may be associated with a reduced risk of low handgrip strength in postmenopausal women.
Read More
